ArticleProbiotics and antimicrobial proteins2026
Characterization of a Novel Endolysin Sb1-LysAEJ as a Biocide and Food-contact Surface Disinfectant for the Control of Staphylococcus aureus.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Staphylococcus aureus (S. aureus) is a globally prevalent pathogen that causes foodborne diseases, posing a serious threat to the food industry and human health. The rapid bactericidal action, high specificity, and low resistance potential of bacteriophage-derived endolysins make them promising alternatives to conventional antimicrobials. In this study, we identified a 1503 bp gene encoding the phage endolysin LysAEJ from the genome of S. aureus phage Sb1 and cloned it into the pET28a expression vector. The encoded endolysin LysAEJ, consisting of 494 amino acid residues (55.5 kDa), was expressed in E. coli BL21 (Rosetta). LysAEJ demonstrated strong bactericidal activity against S. aureus under conditions of pH 9.0-12.0, 4.0-45.0 °C, and in the presence of Ca²⁺. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were 25 µg/mL and 50 µg/mL, respectively. Time‑kill assays using CFU enumeration showed that 100 µg/mL LysAEJ reduced viable S. aureus counts by > 4 log within 30 min. LysAEJ effectively reduced the bacterial load of S. aureus in artificially contaminated milk by approximately 3.9 log CFU/mL and on ham surfaces to below the detection limit (10¹ CFU/cm²) within 6 h at room temperature. It also exhibited high efficiency in removing S. aureus biofilms from food‑contact surfaces (polystyrene, glass, stainless steel), reducing biofilm mass by 83%. Confocal laser scanning microscopy (CLSM) with acridine orange/ethidium bromide staining showed effective killing of cells within the biofilm matrix. Scanning electron microscopy (SEM) revealed significant perforations and morphological damage to cells. Collectively, LysAEJ demonstrates excellent specificity and antimicrobial activity, making it a promising biocontrol agent against S. aureus and its biofilms in diverse food processing environments.
Indexed as
Identifiers
42573933What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.